- Home
- SST vs IOBT Comparison
SST vs IOBT Comparison
Compare SST & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | IOBT |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.7M | 57.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SST | IOBT |
|---|---|---|
| Price | $4.16 | $0.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $10.00 | $3.50 |
| AVG Volume (30 Days) | 30.6K | ★ 768.4K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,784,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $0.32 |
| 52 Week High | $15.00 | $2.79 |
Technical Indicators
Market Signals| Indicator | SST | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 39.57 |
| Support Level | $4.07 | $0.66 |
| Resistance Level | $5.00 | $0.72 |
| Average True Range (ATR) | 0.43 | 0.08 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 37.12 | 11.64 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.